Single-dose azithromycin for the treatment of children with acute otitis media
Carolin A Soley1, Adriano Arguedas
1Instituto de Atención Pediátrica, Universidad de Ciencias Médicas, San José, Costa Rica.
Abstract:
Azithromycin is an azalide with in vitro activity against otitis media pathogens, good middle ear penetration and a prolonged half-life. A total of four clinical trials have evaluated the clinical success rate, safety and compliance of single-dose azithromycin (30 mg/kg) in the treatment of children with otitis media. Among all the patients treated with single-dose azithromycin (30 mg/kg), and presented previously in four published clinical trials, end-of-treatment clinical success was 88% (544 out of 619) and maintained clinical success at the end-of-study was 82% (498 out of 610). Three of the four studies included a mandatory baseline tympanocentesis. The overall end-of-treatment and end-of-study clinical success rates among all culture-positive patients was 84% (222 out of 263) and 80% (210 out of 263), respectively. Per pathogen end-of-treatment clinical success rates observed were 91% (125 out of 137) among patients with Streptococcus pneumoniae, 77% (75 out of 97) among patients with Haemophilus influenzae, 100% (14 out of 14) among patients with Moraxella catarrhalis, 64% (seven out of 11) among patients with baseline Streptococcus pyogenes and 25% (one out of four) among patients with a S. pneumoniae and H. influenzae mixed infection. Clinical success was observed in 90% (106 out of 118) of patients with baseline macrolide-susceptible S. pneumoniae and in 67% (14 out of 21) among patients with baseline macrolide-resistant S. pneumoniae (p = 0.01). Adverse events were uncommon, mostly mild and transitory gastrointestinal complaints, and in the two larger comparative trials, were less frequent than the rates observed with the comparator agents. Compliance was excellent (99-100%). Single-dose azithromycin (30 mg/kg) represents an alternative for the treatment of pediatric patients with uncomplicated acute otitis media, particularly in those geographic regions where high-level S. pneumoniae macrolide resistance is uncommon, and for those patients that require directly observed therapy or when compliance may be a problem.
Insights
Single-dose azithromycin effectively treats acute otitis media in children, showing high success rates and good safety. This antibiotic offers a valuable alternative for pediatric otitis media management.
Area of Science:
- Pharmacology
- Pediatrics
- Infectious Diseases
Background:
- Otitis media is a common childhood infection.
- Azithromycin, an azalide antibiotic, demonstrates in vitro activity against key otitis media pathogens.
- The drug possesses favorable pharmacokinetic properties, including good middle ear penetration and a prolonged half-life.
Purpose of the Study:
- To evaluate the clinical success rate, safety, and compliance of single-dose azithromycin (30 mg/kg) in pediatric patients with acute otitis media.
- To assess treatment outcomes based on pathogen identification and macrolide resistance.
Main Methods:
- Analysis of data from four clinical trials involving single-dose azithromycin (30 mg/kg) treatment.
- Inclusion of baseline tympanocentesis in three of the four studies for pathogen identification.
- Assessment of end-of-treatment and end-of-study clinical success rates, stratified by pathogen and macrolide resistance.
Main Results:
- Overall end-of-treatment clinical success was 88% (544/619) and maintained success at end-of-study was 82% (498/610).
- For culture-positive patients, success rates were 84% (222/263) at end-of-treatment and 80% (210/263) at end-of-study.
- High success rates were observed for Streptococcus pneumoniae (91%) and Moraxella catarrhalis (100%), with lower rates for Haemophilus influenzae (77%) and Streptococcus pyogenes (64%).
- Clinical success was significantly higher in patients with macrolide-susceptible S. pneumoniae (90%) compared to resistant strains (67%, p=0.01).
- Adverse events were infrequent, mild, and transient, primarily gastrointestinal complaints, and less common than with comparator agents in larger trials.
- Compliance was excellent, ranging from 99-100%.
Conclusions:
- Single-dose azithromycin (30 mg/kg) is an effective alternative for treating uncomplicated acute otitis media in children.
- Its use is particularly relevant in regions with low macrolide resistance in S. pneumoniae or when directly observed therapy or compliance is a concern.
Related Concept Videos
01:26Tonsillitis II: Management
01:29Drug Dosing: Infants and Children
01:30Acute Pharyngitis
Acute pharyngitis is the inflammation of the back of the throat (pharynx), commonly resulting in a sore throat. It is a frequently encountered condition that prompts individuals to seek medical advice.
Classification
Acute pharyngitis can be categorized based on its underlying cause:
01:16Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
01:25Dosage Regimen: Multiple Oral Dosage
01:30Tonsillitis I: Introduction
Etiology
Three primary contributing factors have been identified.